LaunchTrends: Gilotrif (US) (Wave 3) | 2014
“LaunchTrends: Gilotrif Wave 3 (US)” is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched non-small-cell lung cancer (NSCLC) drug Gilotrif (Boehringer Ingelheim’s afatinib). In this report, we measure the impact of this new agent on the metastatic NSCLC therapy market based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. We focus on these physicians’ current awareness and perception of Gilotrif relative to other currently available therapies for metastatic NSCLC, their current and anticipated use of Gilotrif, and promotional activity of Gilotrif.
Related Market Assessment Reports
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…
